Cyclo Therapeutics, Inc. (CYTH)
| Previous close | 1.3300 |
| Open | 1.3300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.2600 - 1.3500 |
| 52-week range | 0.8900 - 2.5700 |
| Volume | |
| Avg. volume | 100,379 |
| Market cap | 36.182M |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2300 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.30 |
Simply Wall St.Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- Business Wire
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GAINESVILLE, Fla., March 18, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
- Business Wire
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
GAINESVILLE, Fla., March 14, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, "Methods for Treating Alzheimer’s Disease," with claims that cover the use of Trappsol® Cyclo™ for th
